KRT18P67

Across TCGA pan-cancer cohorts, KRT18P67 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of KRT18P67’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where KRT18P67 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KRT18P67 is over-expressed in tumor.

STAD, ESCA, and UCEC are the cancer types where KRT18P67 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRT18P67 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	All	+0.119	.003	4	view →
ESCA	All	II,III,IV	+0.190	.002	2	view →
UCEC	All	IV	+0.115	.044	2	view →
CHOL	All	All	+0.051	.001	2	view →
COAD	Male	IV	+0.072	.048	1	view →
LUAD	Male	II,III,IV	+0.038	.015	1	view →
KIRP	All	All	+0.018	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

KRT18P67–STAD

Open the STAD breakdown →